Company: GIFLF
Filing Date: 2025-05-12
Form Type: 6-K
Source: 0001104659-25-047168
Chunk: 21

Company: Grifols SA
Filing Date: 2025-05-12
Form: 6-K
Chunk 21
---
5.5x 5.6x 6.1x 6.5x 8.0x

- 29 - Q1 2025 Results NCI Contributions Business Performance Financials Final Remarks Annex In thousand of euros GDS Biotest BPC Haema Profit after tax from continuing operations 135,902 (81,250) 42,044 7,877 Income tax expense (43,595) 12,772 (11,630) (14,477) Financial result 75,601 (30,249) (1,367) 7,407 Amortisation and depreciation (47,490) (54,788) (7,976) (8,696) Consolidated EBITDA 151,386 (8,984) 63,017 23,643 Impact IFRS16- Finance Leases (leases of plasma donation centre properties) (2,452) (8,224) (5,689) (4,695) Restructuring costs 3,036 1,050 - 230 Share of profits assoc core activit 2024 - (4,388) - - Impairment - 19,154 - - Consolidated EBITDA under Credit Agreement 151,970 (1,392) 57,328 19,178 % of non-controlling interest 45% 29% 100% 100% Consolidated EBITDA according to Credit Agreement non-controlling interest 68,387 (403) 57,328 19,178 Cash and cash equivalents (1,981) (41,776) (2,233) (17,219) Financial assets/liabilities with Grifols (1,093,321) 543,038 - - Leasing liabilities (leases of real estate of plasma donation centres) 12,532 59,406 56,606 20,954 Loans and other financial liabilities 4,419 66,347 64 - Total Balance Sheet Net Debt (1,078,351) 627,015 54,437 3,734 Impact IFRS16- Finance Leases (leases of plasma donation centre properties) (12,532) (59,406) (56,606) (20,954) Total Net Financial Debt according to Credit Agreement (1,090,883) 567,609 (2,169) (17,219) Total Net Financial Debt according to Credit Agreement non-controlling